San Francisco Bay Area biotech stories.
Thursday, August 2, 2012
Gilead inks deal for Indian companies for low-cost HIV drug
Gilead Sciences Inc. will work with three Indian drug makers to promote access to a chunk of its portfolio of approved HIV-fighting treatments in developing countries
. Under the deal announced Thursday, Foster City-based Gilead (NASDAQ: GILD) will turn over technology to Mylan Laboratories, Ranbaxy Laboratories Ltd. and Strides Acrolab needed to make Gilead's emtricitabine, or Emtriva.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)